In this video, Fool health-care bureau chief Brenton Flynn outlines the opportunities for Abbott Labs, most notably with its nutrition, pharmaceutical, and diagnostics divisions. Dietary supplements for older adults -- a growing market in the U.S. -- and pharmaceutical potential, both domestically and in emerging markets, are areas for investors to watch. However, one of Abbott's other divisions faces stiff competition and appears to be fighting significant headwinds. Find out more details in the following video.